Candriam S.C.A. Arvinas, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Arvinas, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 524,781 shares of ARVN stock, worth $9.83 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

524,781

Previous 610,458 14.03%

Holding current value

$9.83 Million

Previous $16.3 Million 20.46%

% of portfolio

0.08%

Previous 0.1%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$23.66 - $32.73 $2.03 Million - $2.8 Million	-85,677 Reduced 14.03%	524,781 $12.9 Million
Q2 2024 Aug 05, 2024	BUY	$24.46 - $40.4 $3.62 Million - $5.98 Million	147,904 Added 31.98%	610,458 $16.3 Million
Q1 2024 May 03, 2024	SELL	$36.38 - $52.31 $909,536 - $1.31 Million	-25,001 Reduced 5.13%	462,554 $19.1 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $567,656 - $1.69 Million	40,004 Added 8.94%	487,555 $20.1 Million
Q3 2023 Nov 13, 2023	SELL	$19.64 - $28.21 $392,839 - $564,256	-20,002 Reduced 4.28%	447,551 $8.79 Million
Q2 2023 Aug 08, 2023	SELL	$21.73 - $31.43 $595,271 - $860,993	-27,394 Reduced 5.53%	467,553 $11.6 Million
Q1 2023 May 12, 2023	SELL	$26.15 - $37.26 $1.02 Million - $1.46 Million	-39,055 Reduced 7.31%	494,947 $13.5 Million
Q4 2022 Feb 13, 2023	BUY	$32.47 - $57.24 $477,633 - $842,000	14,710 Added 2.83%	534,002 $18.3 Million
Q3 2022 Nov 10, 2022	BUY	$41.87 - $57.99 $935,585 - $1.3 Million	22,345 Added 4.5%	519,292 $23.1 Million
Q2 2022 Aug 03, 2022	BUY	$36.01 - $74.24 $224,702 - $463,257	6,240 Added 1.27%	496,947 $20.9 Million
Q1 2022 May 13, 2022	SELL	$60.27 - $81.57 $1.9 Million - $2.58 Million	-31,599 Reduced 6.05%	490,707 $33 Million
Q4 2021 Feb 10, 2022	BUY	$65.85 - $96.21 $11.6 Million - $17 Million	176,712 Added 51.13%	522,306 $42.9 Million
Q3 2021 Nov 09, 2021	BUY	$73.2 - $107.87 $6.95 Million - $10.2 Million	94,991 Added 37.9%	345,594 $28.4 Million
Q2 2021 Jul 20, 2021	SELL	$60.45 - $84.26 $2.35 Million - $3.27 Million	-38,811 Reduced 13.41%	250,603 $19.3 Million
Q4 2020 Jan 22, 2021	SELL	$20.19 - $84.93 $637,034 - $2.68 Million	-31,552 Reduced 9.83%	289,414 $24.6 Million
Q3 2020 Oct 19, 2020	SELL	$22.99 - $36.34 $995,903 - $1.57 Million	-43,319 Reduced 11.89%	320,966 $7.58 Million
Q2 2020 Jul 23, 2020	BUY	$29.88 - $56.74 $2.73 Million - $5.19 Million	91,462 Added 33.52%	364,285 $12.2 Million
Q1 2020 May 26, 2020	BUY	$33.0 - $54.5 $561 - $926	17 Added 0.01%	272,823 $11 Million
Q4 2019 Jan 21, 2020	BUY	$15.39 - $44.38 $415,760 - $1.2 Million	27,015 Added 10.99%	272,806 $11,000
Q3 2019 Oct 21, 2019	BUY	$21.55 - $27.61 $5.3 Million - $6.79 Million	245,791 New	245,791 $5,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account